Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Eur J Med Chem. 2017 Sep 29;138:300-312. doi: 10.1016/j.ejmech.2017.06.024. Epub 2017 Jun 15.
The αβδ subtype of the γ-aminobutyric acid (GABA) type A receptors (GABARs) has been shown to be implicated in high-affinity binding of the neuromodulator γ-hydroxybutyric acid (GHB), but may not be the only GHB high-affinity binding sites. Monastrol has been identified as a modulator of GHB high-affinity binding and is furthermore reported as an allosteric modulator selective for the αβδ GABARs. Therefore, structural determinants for selectivity at the two targets were investigated. 39 structural diverse monastrol analogues were synthesized by employing the Biginelli cyclocondensation and examined for modulation of GHB high-affinity binding using the GHB-specific ligand [H]NCS-382 [(E,RS)-6,7,8,9-tetrahydro-5-hydroxy-5H-benzocyclohept-6-ylidene)acetic acid] in rat brain homogenate. Only limited modifications were allowed on the monastrol scaffold in order to maintain modulation of GHB high-affinity binding. However, three analogues of monastrol (11, 12 and 24) enhanced the maximal binding of [H]NCS-382 to a higher maximal level than seen for monastrol itself. Selected compounds were further characterized as modulators at αβδ, αβγ and αβ GABARs. Most of these modulators were shown to have δ-specific GABA-potentiating effects. The dual effect shown for monastrol to modulate the GHB high-affinity binding and αβδ GABAR activity was also shown for the compounds 11, 18 and 24. Compound 29 displayed minimal modulatory effect on GABARs and therefore appears to be a GHB high-affinity binding preferring modulator. However, compounds 34 and 37 were shown to be αβδ GABAR selective modulators, without modulatory effects on GHB high-affinity binding. Thus, our study shows that minor modifications in the structure of monastrol affects the selectivity profile for the two targets under study enabling separation of the dual activity.
γ-氨基丁酸(GABA)A型受体(GABARs)的αβδ亚型已被证明与神经调节剂γ-羟基丁酸(GHB)的高亲和力结合有关,但可能不是唯一的 GHB 高亲和力结合位点。莫那司特已被确定为 GHB 高亲和力结合的调节剂,并且被进一步报道为对αβδ GABARs 具有变构调节作用的选择性调节剂。因此,研究了两个靶标选择性的结构决定因素。通过使用比格内利环缩合合成了 39 种结构多样的莫那司特类似物,并使用 GHB 特异性配体 [H]NCS-382((E,RS)-6,7,8,9-四氢-5-羟基-5H-苯并环庚-6-亚基)乙酸)在大鼠脑匀浆中检查了对 GHB 高亲和力结合的调制。为了保持对 GHB 高亲和力结合的调制,仅允许在莫那司特支架上进行有限的修饰。然而,莫那司特的三个类似物(11、12 和 24)增强了 [H]NCS-382 的最大结合,达到比莫那司特本身更高的最大水平。选择的化合物进一步被表征为αβδ、αβγ和αβ GABARs 的调节剂。这些调节剂中的大多数显示出对δ的 GABA 增强作用。莫那司特调节 GHB 高亲和力结合和αβδ GABAR 活性的双重作用也在化合物 11、18 和 24 中得到显示。化合物 29 对 GABARs 的调节作用最小,因此似乎是一种 GHB 高亲和力结合的优先调节剂。然而,化合物 34 和 37 被显示为αβδ GABAR 选择性调节剂,对 GHB 高亲和力结合没有调节作用。因此,我们的研究表明,莫那司特结构的微小修饰会影响两个研究靶标的选择性谱,从而实现双重活性的分离。